Skip to main content

Table 1 Antimicrobial resistance and β-lactamase production in Neisseria gonorrhoeae isolates (n = 2136) from Russia in 2009–2012

From: Russian gonococcal antimicrobial susceptibility programme (RU-GASP) – resistance in Neisseria gonorrhoeae during 2009–2012 and NG-MAST genotypes in 2011 and 2012

 

Number (%) of resistant isolates

 

2009 (n = 1200)

2010 (n = 407)

2011 (n = 423)

2012 (n = 106)

Ciprofloxacin

533 (44.4)

217 (53.2)

138 (32.6)

27 (25.5)

(R > 0.5 mg/L)a

Penicillin G

115 (9.6)

51 (12.5)

56 (13.2)

12 (11.3)

(R > 1 mg/L)a

Azithromycin

28 (2.3)

20 (4.9)

70 (16.5)

18 (17.0)

(R > 0.5 mg/L)a

Spectinomycin

16 (1.3)

18 (4.4)

49 (11.6)

1 (0.9)

(R > 64 mg/L)a

Ceftriaxone

0

0

0

0

(R > 0.25 mg/L)a

β-lactamase production

4 (0.3)

0

2 (0.5)

0

  1. aBreakpoints for resistance according to the US Clinical and Laboratory Standards Institute [CLSI; 32].
  2. For azithromycin, for which CLSI does not state any breakpoints, the resistance breakpoint from the European Committee on Antimicrobial Susceptibility Testing [EUCAST; http://www.eucast.org/clinical_breakpoints] was used.